Generation and evaluation of anatomy-preserving virtual CT for online adaptive proton therapy.

BACKGROUND: Daily CTs generated by CBCT correction are required for daily replanning in online-adaptive proton therapy (APT) to effectively deal with inter-fractional changes. Out of the currently available methods, the suitability of a daily CT generation method for proton dose calculation also depends on the anatomical site. PURPOSE: We propose an anatomy-preserving virtual CT (APvCT) method as a hybrid method of CBCT correction, which is especially suitable for large anatomy deformations. The accuracy of the hybrid method was assessed by comparison with the corrected CBCT (cCBCT) and virtual CT (vCT) methods in the context of online APT. METHODS: Seventy-one daily CBCTs of four prostate cancer patients treated with intensity modulated proton therapy (IMPT) were converted to daily CTs using cCBCT, vCT, and the newly proposed APvCT method. In APvCT, planning CT (pCT) were mapped to CBCT geometry using deformable image registration with boundary conditions on controlling regions of interest (ROIs) created with deep learning segmentation on cCBCT. The relative frequency distribution (RFD) of HU, mass density and stopping power ratio (SPR) values were assessed and compared with the pCT. The ROIs in the APvCT and vCT were compared with cCBCT in terms of Dice similarity coefficient (DSC) and mean distance-to-agreement (mDTA). For each patient, a robustly optimized IMPT plan was created on the pCT and subsequent daily adaptive plans on daily CTs. For dose distribution comparison on the same anatomy, the daily adaptive plans on cCBCT and vCT were recalculated on the corresponding APvCT. The dose distributions were compared in terms of isodose volumes and 3D global gamma-index passing rate (GPR) at γ(2%, 2 mm) criterion. RESULTS: For all patients, no noticeable difference in RFDs was observed amongst APvCT, vCT, and pCT except in cCBCT, which showed a noticeable difference. The minimum DSC value was 0.96 and 0.39 for contours in APvCT and vCT respectively. The average value of mDTA for APvCT was 0.01 cm for clinical target volume and ≤0.01 cm for organs at risk, which increased to 0.18 cm and ≤0.52 cm for vCT. The mean GPR value was 90.9%, 64.5%, and 67.0% for APvCT versus cCBCT, vCT versus cCBCT, and APvCT versus vCT, respectively. When recalculated on APvCT, the adaptive cCBCT and vCT plans resulted in mean GPRs of 89.5 ± 5.1% and 65.9 ± 19.1%, respectively. The mean DSC values for 80.0%, 90.0%, 95.0%, 98.0%, and 100.0% isodose volumes were 0.97, 0.97, 0.97, 0.95, and 0.91 for recalculated cCBCT plans, and 0.89, 0.88, 0.87, 0.85, and 0.81 for recalculated vCT plans. Hausdorff distance for the 100.0% isodose volume in some cases of recalculated cCBCT plans on APvCT exceeded 1.00 cm. CONCLUSIONS: APvCT contours showed good agreement with reference contours of cCBCT which indicates anatomy preservation in APvCT. A vCT with erroneous anatomy can result in an incorrect adaptive plan. Further, slightly lower values of GPR between the APvCT and cCBCT-based adaptive plans can be explained by the difference in the cCBCT's SPR RFD from the pCT.

Benchmarking a New Circular Cone-based Radiosurgery System against Clinically Tested Radiosurgery System on the same Novel Digital Linear Accelerator Platform.

Objective: To examine the dosimetric characteristics of circular cones, the accuracy of dose modeling and overall treatment delivery of two radiosurgery systems integrated on a linear accelerator (Linac). Materials and Methods: The dosimetric characteristics of circular cones (4-17.5 mm) from Varian (VC) and BrainLAB (BLC) were measured for 6 MV flattening filter free beam from Edge linac using stereotactic field diode and 0.65 cc ionization chamber following established protocols. The Eclipse and iPlan modeled dose distribution for VCs and BLCs were validated with EBT3-film measurement. End-to-end tests were performed using stereotactic phantom having PTW 60008 diode connected to a Dose-1 electrometer. Results: The depth at dose maximum, TRP2010 and dose at 10cm depth of the same size VC and BLC agree within ± 0.7 mm, ± 0.71% and ± 0.81% respectively. Full width at half maximum (FWHM) of any cone beyond 15 mm depth increases at 1% of nominal cone size per 10 mm depth. The penumbra of 4mm and 17.5mm VC at 15 mm depth was 1.1 mm and 1.50 mm. At 300 mm depth, penumbra increased by around 0.4 mm for 4 mm cone and up to 1 mm for cone size ≥12.5 mm. The VCs penumbra values were within ±1mm of the corresponding BLCs. Scatter factors for VCs varies from 0.609 to 0.841 and were within ± 1.0% of corresponding values of BLCs. Agreement between the Eclipse and iPlan computed dose fluence and the EBT3-film measured dose fluence was >98% (γ: 1%@1 mm), and the absolute dose difference was ≤ 2.2%, except for the 4 mm cone in which it was >96% and ≤4.83%. Target localization using cone-beam computed tomography was accurate within ± 0.8 mm and ± 0.3° in translation and rotation. The end-to-end dose delivery accuracy for both radiosurgery systems was within ± 3.62%. Conclusion: The dosimetric characteristics of Varian and BLC cones of same diameter was comparable. Both Eclipse and iPlan cone planning system modeled dose fluences agree well with the EBT3 film measurement. The end-to-end tests revealed an excellent target localization accuracy of Edge linac with satisfactory and comparable absolute dose agreement between Varian and BLC radiosurgery systems and hence these can be interchanged on edge linac.

Implementation and Challenges of International Atomic Energy Agency/American Association of Physicists in Medicine TRS 483 Formalism for Field Output Factors and Involved Uncertainties Determination in Small Fields for TomoTherapy.

PURPOSE: International Atomic Energy Agency published TRS-483 to address the issues of small field dosimetry. Our study calculates the output factor in the small fields of TomoTherapy using different detectors and dosimetric conditions. Furthermore, it estimates the various components of uncertainty and presents challenges faced during implementation. MATERIALS AND METHODS: Beam quality TPR20,10(10) at the hypothetical field size of 10 cm × 10 cm was calculated from TPR20,10(S). Two ionization chambers based on the minimum field width required to satisfy the lateral charge particle equilibrium and one unshielded electron field diode (EFD) were selected. Output factor measurements were performed in various dosimetric conditions. RESULTS: Beam quality TPR20,10(10) has a mean value of 0.627 ± 0.001. The maximum variation of output factor between CC01 chamber and EFD diode at the smallest field size was 11.80%. In source to surface setup, the difference between water and virtual water was up to 9.68% and 8.13%, respectively, for the CC01 chamber and EFD diode. The total uncertainty in the ionization chamber was 2.43 times higher compared to the unshielded EFD diode at the smallest field size. CONCLUSIONS: Beam quality measurements, chamber selection procedure, and output factors were successfully carried out. A difference of up to 10% in output factor can occur if density scaling for electron density in virtual water is not considered. The uncertainty in output correction factors dominates, while positional and meter reading uncertainty makes a minor contribution to total uncertainty. An unshielded EFD diode is a preferred detector in small fields because of lower uncertainty in measurements compared to ionization chambers.

A novel hybrid 3D dose reconstruction approach for pre-treatment verification of intensity modulated proton therapy plans.

AIM: A novel hybrid three-dimensional (3D) dose reconstruction method, based on planar dose measured at a single shallower depth, was developed for use as patient-specific quality assurance (PSQA) of intensity modulated proton therapy (IMPT) plans. The accuracy, robustness and sensitivity of the presented method were validated for multiple IMPT plans of varying complexities. METHODS AND MATERIALS: An in-house MATLAB program was developed to reconstruct 3D dose distribution from the planar dose (GyRBE) measured at 3 g cm-2 depth in water or solid phantom using a MatriXX PT ion chamber array. The presented method was validated extensively for 11 single-field optimization (SFO) and multi-field optimization (MFO) plans on Proteus Plus. A total of 47 reconstructed planar doses at different depths were compared against the corresponding RayStation treatment planning system (TPS) and MatriXX PT measurement using a gamma passing rate (γ%) evaluated for 3%/3 mm. The robustness of the reconstruction method with respect to depth, energy layers, field dimensions and complexities in the spot intensity map (SIM) were analysed and compared against the standard PSQA. The sensitivity of the reconstruction method was tested for plans with intentional errors. RESULTS: The presented reconstruction method showed excellent agreement (mean γ% > 98%) and robustness with both TPS-calculated and measured dose planes at all depths (2.97-30 g cm-2), energy layers (82.1-225.5 MeV), field dimensions, target volume (17.7-1000 cm3) and SIMs from both SFO and MFO plans. In comparison to the overall mean ± SD γ% from standard PSQA, the reconstruction method showed reductions in mean γ% within 1% for both standard cubes and clinical plans. The reconstruction method was sensitive enough to detect intentional spot positional errors in a selected energy layer of a plan. CONCLUSION: The presented hybrid reconstruction method is sufficiently accurate, robust and sensitive to estimate planar dose at any user-defined depth. It simplifies the measurement setup and eliminates multiple depth measurements.

Leaf open time sinogram (LOTS): a novel approach for patient specific quality assurance of total marrow irradiation.

There is no ideal detector-phantom combination to perform patient specific quality assurance (PSQA) for Total Marrow (TMI) and Lymphoid (TMLI) Irradiation plan. In this study, 3D dose reconstruction using mega voltage computed tomography detectors measured Leaf Open Time Sinogram (LOTS) was investigated for PSQA of TMI/TMLI patients in helical tomotherapy. The feasibility of this method was first validated for ten non-TMI/TMLI patients, by comparing reconstructed dose with (a) ion-chamber (IC) and helical detector array (ArcCheck) measurement and (b) planned dose distribution using 3Dγ analysis for 3%@3mm and dose to 98% (D98%) and 2% (D2%) of PTVs. Same comparison was extended for ten treatment plans from five TMI/TMLI patients. In all non-TMI/TMLI patients, reconstructed absolute dose was within ± 1.80% of planned and IC measurement. The planned dose distribution agreed with reconstructed and ArcCheck measured dose with mean (SD) 3Dγ of 98.70% (1.57%) and 2Dγ of 99.48% (0.81%). The deviation in D98% and D2% were within 1.71% and 4.10% respectively. In all 25 measurement locations from TMI/TMLI patients, planned and IC measured absolute dose agreed within ± 1.20%. Although sectorial fluence verification using ArcCHECK measurement for PTVs chest from the five upper body TMI/TMLI plans showed mean ± SD 2Dγ of 97.82% ± 1.27%, the reconstruction method resulted poor mean (SD) 3Dγ of 92.00% (± 5.83%), 64.80% (± 28.28%), 69.20% (± 30.46%), 60.80% (± 19.37%) and 73.2% (± 20.36%) for PTVs brain, chest, torso, limb and upper body respectively. The corresponding deviation in median D98% and D2% of all PTVs were < 3.80% and 9.50%. Re-optimization of all upper body TMI/TMLI plans with new pitch and modulation factor of 0.3 and 3 leads significant improvement with 3Dγ of 100% for all PTVs and median D98% and D2% < 1.6%. LOTS based PSQA for TMI/TMLI is accurate, robust and efficient. A field width, pitch and modulation factor of 5 cm, 0.3 and 3 for upper body TMI/TMLI plan is suggested for better dosimetric outcome and PSQA results.